Friday, 9 July 2021
Cystic Fibrosis NZ is very pleased to share that Vertex has submitted its application for funding of Trikafta to Pharmac.
This is a major step forward in securing access to Trikafta for Kiwis with CF.
The application to Pharmac for funding follows Vertex’s application in June to Medsafe for approval of the use of Trikafta in New Zealand. Medsafe granted the application priority status, enabling a shorter time for evaluation.
In its press release Vertex explained the company "is willing to work collaboratively and flexibly with Pharmac and we look forward to dialogue and the next steps in the process.
"Vertex has made significant progress in New Zealand over the last few months and is committed to ensuring all eligible patients have sustainable access to our triple combination treatment as soon as possible".
Cystic Fibrosis NZ is very appreciative of the commitment by Medsafe and Pharmac to consider the applications for Trikafta in parallel, and we look forward to Kiwis with CF having access to Trikafta as soon as possible.
Both Pharmac's Respiratory Subcommittee and Pharmacology and Therapeutics Advisory Committee (PTAC) will assess the scientific evidence on the medicine within the next few months, who will make recommendations to Pharmac on whether it should fund the medicine or not.
"We will continue to work with all parties, including Pharmac, to ensure they understand how challenging life with CF is and the life-changing benefits that Trikafta will bring," says Jane Bollard, Cystic Fibrosis NZ Chief Executive.
We thank everyone in the CF community who has been willing to share their story as part of this campaign.
Vertex statement - to come
